TY - JOUR
T1 - Prospective analysis of association between statin use and breast cancer risk in the women's health initiative
AU - Desai, Pinkal
AU - Chlebowski, Rowan
AU - Cauley, Jane A.
AU - Manson, Joann E.
AU - Wu, Chunyuan
AU - Martin, Lisa W.
AU - Jay, Allison
AU - Bock, Cathryn
AU - Cote, Michele
AU - Petrucelli, Nancie
AU - Rosenberg, Carol A.
AU - Peters, Ulrike
AU - Agalliu, Ilir
AU - Budrys, Nicole
AU - Abdul-Hussein, Mustafa
AU - Lane, Dorothy
AU - Luo, Juhua
AU - Park, Hannah Lui
AU - Thomas, Fridtjof
AU - Wactawski-Wende, Jean
AU - Simon, Michael S.
PY - 2013/10
Y1 - 2013/10
N2 - Background: Statins are a class of cholesterol-lowering drugs that affect many intracellular pathways that may have implications for chemoprevention against cancer. Epidemiologic data on statins and breast cancer are conflicting. Weanalyzed updated data from the Women's Health Initiative (WHI) to assess the relationship between statins and breast cancer risk. Methods: The population included 154,587 postmenopausal women ages 50 to 79 years, with 7,430 pathologically confirmed cases of breast cancer identified over an average of 10.8 (SD, 3.3) years. Information on statins was collected at baseline and years one, three, six, and nine. Self- and interviewer-administered questionnaires were used to collect information on risk factors. Cox proportional hazards regression was used to calculate HRs with 95% confidence intervals (CI) to evaluate the relationship between statin use and cancer risk. Statistical tests were two-sided. Results: Statins were used by 11,584 (7.5%) women at baseline. The annualized rate of breast cancer was 0.42% among statin users and 0.42% among nonusers. The multivariable adjusted HR of breast cancer for users versus nonusers was 0.94 (95% CI, 0.83-1.06). In the multivariable-adjusted, time-dependent model, the HR for simvastatin was 0.87 (95% CI, 0.71-1.07). There was no significant trend by overall duration of use (P value for trend 0.68). There was no effect of tumor stage, grade, or hormone receptor status. Conclusion: Overall, statins were not associated with breast cancer risk. Impact: Our study is one of the largest prospective observational studies on this topic, and substantially adds to the literature suggesting no relationship between statins and breast cancer risk.
AB - Background: Statins are a class of cholesterol-lowering drugs that affect many intracellular pathways that may have implications for chemoprevention against cancer. Epidemiologic data on statins and breast cancer are conflicting. Weanalyzed updated data from the Women's Health Initiative (WHI) to assess the relationship between statins and breast cancer risk. Methods: The population included 154,587 postmenopausal women ages 50 to 79 years, with 7,430 pathologically confirmed cases of breast cancer identified over an average of 10.8 (SD, 3.3) years. Information on statins was collected at baseline and years one, three, six, and nine. Self- and interviewer-administered questionnaires were used to collect information on risk factors. Cox proportional hazards regression was used to calculate HRs with 95% confidence intervals (CI) to evaluate the relationship between statin use and cancer risk. Statistical tests were two-sided. Results: Statins were used by 11,584 (7.5%) women at baseline. The annualized rate of breast cancer was 0.42% among statin users and 0.42% among nonusers. The multivariable adjusted HR of breast cancer for users versus nonusers was 0.94 (95% CI, 0.83-1.06). In the multivariable-adjusted, time-dependent model, the HR for simvastatin was 0.87 (95% CI, 0.71-1.07). There was no significant trend by overall duration of use (P value for trend 0.68). There was no effect of tumor stage, grade, or hormone receptor status. Conclusion: Overall, statins were not associated with breast cancer risk. Impact: Our study is one of the largest prospective observational studies on this topic, and substantially adds to the literature suggesting no relationship between statins and breast cancer risk.
UR - http://www.scopus.com/inward/record.url?scp=84886416119&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84886416119&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-13-0562
DO - 10.1158/1055-9965.EPI-13-0562
M3 - Article
C2 - 23975947
AN - SCOPUS:84886416119
SN - 1055-9965
VL - 22
SP - 1868
EP - 1876
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 10
ER -